专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20210238631A1 ADENO-ASSOCIATED VIRUS VECTOR 有权
公开(公告)号：US20210238631A1
公开(公告)日：2021-08-05
申请号：US17072676
申请日：2020-10-16
申请人： KING'S COLLEGE LONDON , ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
发明人： Ralph Michael Linden
IPC分类号： C12N15/86 , C07K14/005 , A61P27/02 , A61P27/06 , A61P1/16 , A61P25/00 , A61K48/00
摘要： Disclosed herein is a recombinant adeno-associated virus (AAV) vector comprising (a) a variant AAV2 capsid protein, wherein the variant AAV2 capsid protein comprises at least four amino acid substitutions with respect to a wild type AAV2 capsid protein; wherein the at least four amino acid substitutions are present at the following positions in an AAV2 capsid protein sequence: 457, 492, 499 and 533; and (b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product.

12. 发明申请

US20210230151A1 Crystalline Forms of 4-(5-(4,7-Dimethylbenzofuran-2-YL)-1,2,4-Oxadiazol-3-YL)Benzoic Acid and Processes for Their Preparation 有权
公开(公告)号：US20210230151A1
公开(公告)日：2021-07-29
申请号：US17109758
申请日：2020-12-02
申请人： King's College London
发明人： Ronnie Maxwell Lawrence , Edwin Aret , Alan David Borthwick , Jane Theresa Brown , Jonathan Patrick Thomas Corcoran , Maria Beatriz De Castro Vasconcelos Goncalves , Sarkis Barrett Kalindjian
IPC分类号： C07D413/04
摘要： The present invention pertains generally to the field of therapeutic compounds, and more specifically to crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (referred to herein as “BHBA-001”), which, inter alia, is a (selective) retinoic acid receptor beta (RΛRβ) (e.g., RΛRβ2) agonist. The present invention also pertains to pharmaceutical compositions comprising such crystalline forms, and the use of such crystalline forms and compositions, both in vitro and in vivo, to (selectively) activate RΛRβ (e.g., RΛRβ2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RARβ (e.g., RΛRβ2), that are ameliorated by the activation of RΛRβ (e.g., RΛRβ2), etc., including, e.g., neurological injuries such as spinal cord injuries.

13. 发明授权

US11033738B2 Apparatus for treatment of snoring and sleep apnoea 有权
公开(公告)号：US11033738B2
公开(公告)日：2021-06-15
申请号：US15540522
申请日：2016-02-05
申请人： KING'S COLLEGE LONDON , GUY'S AND ST. THOMAS' NHS FOUNDATION TRUST
发明人： Joerg Sebastien Steier
IPC分类号： A61N1/36 , A61N1/04
摘要： A portable, battery powered apparatus (10) generates an electrical signal between electrodes (15a, 15b) to be applied to the skin of a patient for reduction or prevention of snoring or obstructive sleep apnoea. The signal comprises electrical stimulation at a frequency of 1-100 Hz and the signal comprises a stimulation free period of at least 0.5 seconds every 20 seconds, avoiding muscle fatigue when used for long periods, e.g. overnight.

14. 发明申请

US20210032317A1 VISTA-IG FOR TREATMENT OF AUTOIMMUNE, ALLERGIC AND INFLAMMATORY DISORDERS 有权
公开(公告)号：US20210032317A1
公开(公告)日：2021-02-04
申请号：US16820116
申请日：2020-03-16
申请人： THE TRUSTEES OF DARTMOUTH COLLEGE , KING'S COLLEGE LONDON
发明人： Randolph J. Noelle , Sabrina Ceeraz , Isabelle LeMercier , Elizabeth Nowak , Janet Lines
IPC分类号： C07K16/18 , A61K39/395 , A61K38/21 , C07K16/30 , C07K16/28 , C07K14/705
摘要： The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig). The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions.

15. 发明授权

US10899818B2 Therapeutic agents 有权
公开(公告)号：US10899818B2
公开(公告)日：2021-01-26
申请号：US16877008
申请日：2020-05-18
申请人： KING'S COLLEGE LONDON
发明人： John Maher , Daniela Yordanova Achkova , Lynsey May Whilding , Benjamin Owen Draper
IPC分类号： A01N63/00 , A61K48/00 , C07K14/725 , C07K14/53 , C07K14/54 , C07K14/705 , C12N5/0783
摘要： An immunoresponsive cell, such as a T-cell expressing (i) a second generation chimeric antigen receptor comprising: (a) a signalling region; (b) a co-stimulatory signalling region; (c) a transmembrane domain; and (d) a binding element that specifically interacts with a first epitope on a target antigen; and (ii) a chimeric costimulatory receptor comprising (e) a co-stimulatory signalling region which is different to that of (b); (f) a transmembrane domain; and g) a binding element that specifically interacts with a second epitope on a target antigen. This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.

16. 发明授权

US10703794B2 Therapeutic agents 有权
公开(公告)号：US10703794B2
公开(公告)日：2020-07-07
申请号：US15749016
申请日：2016-07-28
申请人： KING'S COLLEGE LONDON
发明人： John Maher , Daniela Yordanova Achkova , Lynsey May Whilding , Benjamin Owen Draper
IPC分类号： A01N63/00 , A61K48/00 , C07K14/725 , C07K14/53 , C07K14/54 , C07K14/705 , C12N5/0783
摘要： An immunoresponsive cell, such as a T-cell expressing (i) a second generation chimeric antigen receptor comprising: (a) a signalling region; (b) a co-stimulatory signalling region; (c) a transmembrane domain; and (d) a binding element that specifically interacts with a first epitope on a target antigen; and (ii) a chimeric costimulatory receptor comprising (e) a co-stimulatory signalling region which is different to that of (b); (f) a transmembrane domain; and (g) a binding element that specifically interacts with a second epitope on a target antigen. This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.

17. 发明授权

US10609291B2 Automatic exposure control for endoscopic imaging 有权
公开(公告)号：US10609291B2
公开(公告)日：2020-03-31
申请号：US15328715
申请日：2015-07-17
申请人： KING'S COLLEGE LONDON
发明人： Frederic Festy , Richard Cook , Timothy Watson
IPC分类号： H04N5/235 , H04N5/353 , A61B1/06 , A61B1/00 , A61B1/05 , G02B23/20 , A61B1/045 , G02B23/24 , H04N5/225
摘要： An endoscopic apparatus and method to capture an image of in-vivo tissue with automatic exposure control. For example, the method includes capturing image data on an image sensor and analyzing an indication of brightness of each pixel to determine whether the captured image data is saturated. When the image data is saturated, the method includes reducing the exposure period by a first increment, and repeating the capturing and analyzing steps until the captured image data is not saturated. When the captured image data is not saturated, in some embodiments, the method includes analyzing the indication of brightness of each pixel compared to a threshold indicative of use of a proportion of an available dynamic range of the image sensor, and when it is determined that the threshold has not been reached, increasing the exposure period by a second increment that has a magnitude relative to the first increment.

18. 发明申请

US20190247396A1 DENTAL TREATMENT 审中-公开
公开(公告)号：US20190247396A1
公开(公告)日：2019-08-15
申请号：US16343634
申请日：2017-10-20
申请人： KING'S COLLEGE LONDON
发明人： Paul Thomas SHARPE
IPC分类号： A61K31/506 , A61K9/00 , A61K31/404 , A61K47/42 , A61K31/433 , A61K45/06 , A61P1/02
CPC分类号： A61K31/506 , A61K6/0044 , A61K6/0067 , A61K9/0053 , A61K9/2054 , A61K31/404 , A61K31/426 , A61K31/433 , A61K38/1841 , A61K38/1875 , A61K45/06 , A61K47/42 , A61P1/02 , A61K2300/00
摘要： A pharmaceutically acceptable small molecule which inhibits GSK-3 activity, such as BIO, CHIR99021 or tideglusib; are used in the repair or regeneration of dentine. Combinations with matrix materials forming dental implants are also described and claimed.

19. 发明授权

US09990863B2 Perfusion phantom device 有权
公开(公告)号：US09990863B2
公开(公告)日：2018-06-05
申请号：US14774506
申请日：2014-03-10
申请人： KING'S COLLEGE LONDON
发明人： Amedeo Chiribiri , Eike Nagel , Niloufar Zarinabad Nooralipour , Roman Wesolowski
IPC分类号： G09B23/30 , G09B23/28 , A61B6/00 , G01R33/58 , A61B17/00 , G01R33/563
CPC分类号： G09B23/286 , A61B6/583 , A61B2017/00716 , G01R33/56366 , G01R33/58 , G09B23/303
摘要： The invention relates to a phantom device for reproducing the fluid perfusion in a body, said device comprising a phantom organ that may be introduced into a scanner, said phantom organ comprising a housing in which are defined a plurality of fluid channels, suitably of differing cross-sectional areas; a feed tube arranged to supply liquid to a first end of all of said channels and means for collecting liquid from the other end of the channels. Alternatively or additionally, the device may comprise an element comprising a phantom heart through which fluid can flow, wherein the phantom heart comprises a first chamber representing a right atrium which is arranged to receive fluid from a fluid supply, a second chamber representing a right ventricle which receives fluid leaving said first chamber, a third chamber representing a left atrium which receives fluid leaving the second chamber and a fourth chamber representing left ventricle which receives fluid leaving the third chamber; and wherein a phantom thoracic system is interposed between the second chamber and the third chamber.Uses of the device in quality control, validation or calibration of monitoring devices such as magnetic resonance (MR) or computerized tomography (CT) scanners, in teaching or training of machine operatives or for research purposes including for research into scanners, scanning techniques or reagents such as contrast agents used in such processes, form further aspects of the invention.

20. 发明授权

US09381244B2 VISTA modulators for diagnosis and treatment of cancer 有权
标题翻译：用于诊断和治疗癌症的VISTA调节剂
公开(公告)号：US09381244B2
公开(公告)日：2016-07-05
申请号：US14021353
申请日：2013-09-09
申请人： THE TRUSTEES OF DARTMOUTH COLLEGE
发明人： Randolph Noelle
IPC分类号： A61K39/395 , C07K16/28 , A61K35/00 , A61K45/06 , A61K35/17 , C12N15/113 , A61K39/39 , A61K39/00
CPC分类号： A61K39/39566 , A61K35/17 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K45/06 , A61K47/6851 , A61K2039/505 , A61K2039/507 , A61K2039/5152 , A61K2039/5256 , A61K2039/55516 , C07K16/2827 , C07K16/2878 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2319/30 , C07K2319/32 , C12N15/113 , C12N15/1138 , C12N2310/14 , C12N2710/10034 , C12N2710/10043 , Y02A50/386 , Y02A50/41 , Y02A50/412 , A61K31/00
摘要： The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).
摘要翻译：本公开涉及用于在有需要的患者中激活免疫应答的组合物和治疗方法。在优选的实施方案中，本发明的方法和组合物能够拮抗VISTA的活性，VISTA是有助于免疫耐受的天然存在的“检查点”蛋白质，任选地与第二检查点途径的拮抗剂如PD-1组合。例如，这些方法和组合物可适用于预防和治疗结肠癌或其它癌症。在本文中证明了一种示例性的VISTA拮抗剂，特别是抗-VISTA抗体，以在体外和体内激活针对癌细胞的免疫应答，由此赋予降低肿瘤负荷的保护性抗肿瘤免疫。另外，当将VISTA拮抗剂与第二检查点蛋白拮抗剂，特别是抗PD-1配体（PD-L1）的抗体组合使用时，观察到附加益处。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式